ERBB2 and breast neoplasm: On the contrary, high RGS16 expression in breast tumors attenuates the growth factor-induced PI3K signaling pathway, thereby inhibiting proliferation, human epidermal growth factor receptor 2 activation and resistance to chemotherapeutic agents in breast tumor cells (Liang et al., 2009).